Colorectal cancer is the third most common cancer globally, with a high mortality rate due to metastatic progression, particularly in the liver. Surgical resection remains the main curative treatment, but only a small subset of patients is eligible for surgery at diagnosis. For patients with initially unresectable colorectal liver metastases (CRLM), neoadjuvant chemotherapy can downstage tumors, potentially making surgery feasible. This study investigates whether radiomic signatures —quantitative imaging biomarkers derived from baseline CT scans— can non-invasively predict chemotherapy response in patients with unresectable CRLM, offering a pathway toward personalized treatment planning.